Heron Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Heron Therapeutics is Craig Collard, benoemd in Apr2023, heeft een ambtstermijn van 1.58 jaar. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 285.38K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 3.2 jaar.
Belangrijke informatie
Craig Collard
Algemeen directeur
US$5.5k
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 1.6yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 1.4yrs |
| Gemiddelde ambtstermijn bestuur | 3.2yrs |
Recente managementupdates
Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03CEO
Craig Collard (58 yo)
1.6yrs
Tenure
US$5,486
Compensatie
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$5.49k | 0.18% $ 285.4k | |
| Executive VP & CFO | 1.4yrs | US$1.76m | 0.071% $ 115.6k | |
| Executive VP & Chief Development Officer | 1.4yrs | US$1.71m | 0.068% $ 110.3k | |
| Vice President of Marketing | 1.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Human Resources | 9.2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens | |
| Executive Director | no data | geen gegevens | geen gegevens |
1.4yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HRTX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% $ 285.4k | |
| Independent Director | 10.8yrs | US$11.02m | 0.034% $ 55.5k | |
| Independent Director | 8.4yrs | US$70.51k | 0.034% $ 55.9k | |
| Director | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.2yrs | US$65.63k | 0.035% $ 56.7k | |
| Independent Chairman | 1.8yrs | US$545.53k | 0.0062% $ 10.1k | |
| Independent Director | 3.2yrs | US$55.00k | 0.035% $ 56.7k |
3.2yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HRTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).